The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies
The primary aim of the ProgStar studies is to assess the natural history of the progression of atrophy secondary to Stargardt disease. The ProgStar studies are comprised of retrospective and prospective observational studies. The retrospective study includes clinical examination findings and images collected between 2008 and 2014. The prospective study consists of a 24 month observational period from 2013/2014 for two years, with one visit every six months. The study population will include 250 Stargardt patients in the retrospective study and 250 Stargardt patients in the prospective study recruited currently at 9 clinical centers across the U.S. and Europe. The enrollment of a large population of children and adults with Stargardt disease will assist in evaluating efficacy measures for future clinical trials. The outcomes of interest are measured via imaging (i.e., spectral-domain optical coherence tomography, fundus autofluorescence) and psychophysical testing (i.e., visual acuity, microperimetry).